AstraZeneca Q2 profit jumps on drug sales
Anglo-Swedish pharmaceutical company AstraZeneca said on Thursday that second-quarter net profit jumped to $2.1 billion (15.35 billion kronor) on strong performance across emerging markets and key drug sales.
AstraZeneca said profit after tax rose 23 percent to $2.11 billion in the three months to the end of June compared with the equivalent figure in 2009, causing it to lift its full-year profits forecast.
Analysts had estimated net profits at a lower level of $1.94 billion for the second quarter, according to Dow Jones Newswires. Group sales grew one percent to $8.18 billion in the quarter, boosted by sales of cholesterol drug Crestor, anti-psychotic drug Seroquel and asthma treatment Symbicort.
"Our second-quarter performance reflects continued strong growth in our emerging markets and good performance for key brands," CEO David Brennan said in the group's earnings statement.
Britain's second-biggest drugmaker, which reports in dollars, increased its full-year earnings per share target to a range of $6.35 to $6.65. It is the second time in three months that it has raised the core target.
AstraZeneca faces a steep drop in sales over coming years. Seven of its drugs, including three bestsellers, face generic competition by 2014 -- a higher ratio than major European competitors.
However, the group won a major boost on Wednesday when a US Food and Drug Administration panel backed the use of ticagrelor, a proposed anti-clotting drug developed by AstraZeneca, despite concerns the product might not work in US patients.
Also on Thursday, the company increased its target for net share repurchases for 2010 to $2 billion, double an initial target.
Comments
See Also
AstraZeneca said profit after tax rose 23 percent to $2.11 billion in the three months to the end of June compared with the equivalent figure in 2009, causing it to lift its full-year profits forecast.
Analysts had estimated net profits at a lower level of $1.94 billion for the second quarter, according to Dow Jones Newswires. Group sales grew one percent to $8.18 billion in the quarter, boosted by sales of cholesterol drug Crestor, anti-psychotic drug Seroquel and asthma treatment Symbicort.
"Our second-quarter performance reflects continued strong growth in our emerging markets and good performance for key brands," CEO David Brennan said in the group's earnings statement.
Britain's second-biggest drugmaker, which reports in dollars, increased its full-year earnings per share target to a range of $6.35 to $6.65. It is the second time in three months that it has raised the core target.
AstraZeneca faces a steep drop in sales over coming years. Seven of its drugs, including three bestsellers, face generic competition by 2014 -- a higher ratio than major European competitors.
However, the group won a major boost on Wednesday when a US Food and Drug Administration panel backed the use of ticagrelor, a proposed anti-clotting drug developed by AstraZeneca, despite concerns the product might not work in US patients.
Also on Thursday, the company increased its target for net share repurchases for 2010 to $2 billion, double an initial target.
Join the conversation in our comments section below. Share your own views and experience and if you have a question or suggestion for our journalists then email us at [email protected].
Please keep comments civil, constructive and on topic – and make sure to read our terms of use before getting involved.
Please log in here to leave a comment.